The advent has found that the use of some of the drugs in this class has led to significantly improved outcomes, creating a push for the use of SGLT-2 inhibitors as a first-line agent, especially in patients who have type 2 diabetes mellitus with high cardiovascular risk [6,7]. This evidence concerns the gene SLC5A2 and diabetes mellitus.